BioCardia is advancing two regulatory programs, targeting a CardiAMP HF Shonin pre-market submission in 2026 and a Helix follow-on De Novo pre-submission in the current quarter. The timelines matter because PMDA support could lead to market clearance in 2027, while independent FDA clearance could broaden partnering opportunities.

Key Highlights

  • BioCardia is working toward a CardiAMP HF Shonin pre-market submission to Japan’s PMDA in 2026.
  • PMDA support and a successful review could lead to CardiAMP HF market clearance in 2027.
  • BioCardia is preparing a Shonin pre-market application for Japan’s Pharmaceutical and Medical Device Agency, targeting submission during 2026.
  • The CardiAMP HF II confirmatory study is enrolling in the United States and may support a U.S. Premarket Approval application, according to FDA feedback.

BioCardia, Inc. (NASDAQ: BCDA) is a biotechnology company advancing regulatory milestones for its cardiovascular therapies and delivery technology. The company is targeting a CardiAMP HF submission in Japan during 2026 and plans to move its Helix program into another FDA review step during the current quarter.

CardiAMP HF and Helix Move Toward Review

BioCardia is preparing a Shonin pre-market application for Japan’s Pharmaceutical and Medical Device Agency, after supplying detailed answers to consultation questions. The CardiAMP HF II confirmatory study is enrolling in the United States. The FDA’s Center for Biologics Evaluation and Research has indicated that the study may support a Premarket Approval application.

Potential Clearance and Partnering Path

The statement concerns the Japanese regulatory pathway and its potential outcome. The company also identified the CardiAMP HF II study as a possible basis for a U.S. Premarket Approval application.